Intellia Therapeutics (NTLA) Operating Expenses (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Operating Expenses data on file, last reported at $115.6 million in Q1 2026.

• On a quarterly basis, Operating Expenses fell 15.9% year-over-year to $115.6 million in Q1 2026; TTM through Mar 2026 was $486.8 million, a 17.02% decrease from a year earlier, with the FY2025 full-year figure at $508.7 million, down 14.1% from the prior year.
• Operating Expenses for Q1 2026 stood at $115.6 million, down from $121.7 million in the prior quarter.
• Over the last five years, Operating Expenses for NTLA reached as high as $155.5 million in Q1 2022 and fell as low as $112.3 million in Q2 2022.
• Historically, Operating Expenses has averaged $134.0 million across 5 years, with a median of $137.4 million in 2025.
• Across the five-year window, Operating Expenses jumped 194.11% in 2022 and decreased 19.89% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $123.7 million in 2022, then grew by 11.58% to $138.0 million in 2023, then gained by 8.22% to $149.3 million in 2024, then slipped by 18.48% to $121.7 million in 2025, then slipped by 5.05% to $115.6 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $115.6 million in Q1 2026, $121.7 million in Q4 2025, and $125.3 million in Q3 2025.